Skip to main content
. Author manuscript; available in PMC: 2013 May 1.
Published in final edited form as: J Pharm Pharmacol. 2012 Feb 21;64(5):727–734. doi: 10.1111/j.2042-7158.2012.01463.x

Fig. 6.

Fig. 6

Docking simulation of irinotecan and panaxadiol on the caspase-3 protein. Panaxadiol (PD) and irinotecan (IRN) bind to distinct binding sites on the protein. A surface and ribbon view is shown above (a), while an insight ligand-site model is shown below (b).